Cardiovascular Biotech Misses MAb Era, Looks Ahead To Gene, Cell Therapy
Biotechnology R&D in cardiovascular disease slowed in the decade following the approval of the pioneering monoclonal antibody ReoPro, but emerging biotechnologies hold the potential for a resurgence of biologics amidst the small molecules that dominate the current CV pipeline
You may also be interested in...
AstraZeneca's experience with its failed anticoagulant Exanta (ximelagatran) will provide the company an advantage going forward in developing new oral anticoagulants, VP and Cardiovascular Therapy Area Head Gunnar Olsson maintained
The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011